Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).-MedSci.cn

Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).

Magbanua, MJM; Savenkov, OO; Asmus, E; Ballman, KV; Scott, JH; Park, J; Dickler, MN; Partridge, AH; Carey, LA; Winer, EP; Rugo, HS

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务